JW THERAP-B News

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

Express News | JW (Cayman) Therapeutics - Pwc Has Tendered Resignation to Board as Auditor

ReutersOct 31 04:31 ET

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Stock Rockets 31% But Many Are Still Ignoring The Company

Simply Wall StOct 18 18:36 ET

JW THERAP-B: 2024 INTERIM REPORT

HKEXSep 26 04:34 ET · Announcements

Pharmaron -B (02126) fell 42.80%, now at 1.300 yuan, hitting a 52-week low.

As of 11:34, Wuxi Apptec -B (02126) fell by 42.80% from the previous closing price to 1.300 yuan, hitting a 52-week low; the volume was 0.0227 million shares, with a turnover of 0.0294 million Hong Kong dollars.

金吾財訊Sep 8 23:34 ET

WuXi AppTec-B (02126) granted a total of 2.0391 million share purchase rights and a total of 0.6696 million restricted share units.

WuXi AppTec-B (02126) announced in a notice that on September 2, 2024, in accordance with October 14, 2020...

Zhitong FinanceSep 2 07:31 ET

WuXi Biologics-B (02126) appointed Chen Bingjun as an independent non-executive director.

Pharmaron-B (02126) announced that Chen Bingjun has been appointed as an independent non-executive director, effective from August 2, 2024...

Zhitong FinanceAug 28 07:52 ET

WuXi AppTec Group (02126) released its interim performance, achieving revenue of 86.815 million yuan. Leading product BeiNuoDa has continued to make significant progress in commercialization.

WuXi AppTec-B (02126) released the interim performance for the six months ended June 30, 2024, the group's period...

Zhitong FinanceAug 28 04:59 ET

Express News | JW (Cayman) Therapeutics H1 Revenue RMB 86.8 Million

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Gross Margin 50.4%

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Gross Profit RMB 43.7 Million

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Net Income RMB -240.3 Million

ReutersAug 28 04:36 ET

JW THERAP-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEXAug 28 04:35 ET · Announcements

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Might Not Be As Mispriced As It Looks After Plunging 27%

Simply Wall StAug 27 19:08 ET

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva in Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma

PR NewswireAug 27 05:00 ET

Express News | JW (Cayman) Therapeutics - Nmpa Approved Supplemental Biological License Application for Anti-Cd19 Autologous Chimeric Antigen Receptor T Product

ReutersAug 27 04:37 ET

WuXi AppTec-B (02126.HK) plans to hold a board of directors meeting on August 28th to approve mid-term performance.

On August 14th, Gelonghui reported that Pharma Giant-B (02126.HK) announced that the board of directors' meeting will be held on Wednesday, August 28, 2024, to (including) (i) consider and approve the unaudited interim results of the group for the six months ending June 30, 2024 and their publication; and (ii) handle any other matters.

Gelonghui FinanceAug 14 04:47 ET

Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.

The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.

Zhitong FinanceAug 7 01:50 ET